Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)
Calithera Biosciences, Inc. (CALA - Free Report) is a clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CALA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Calithera Biosciences could be a solid choice for investors.
Current Quarter Estimates for CALA
In the past 30 days, Calithera Biosciences’ trend has been pretty favorable, with estimates narrowing from a loss of 29 cents a share 30 days ago, to a loss of 25 cents today, a move of 13.8%.
Current Year Estimates for CALA
Meanwhile, Calithera Biosciences current year figures are also looking quite promising. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 96 cents per share 30 days ago to a loss of 88 cents per share today, an increase of 8.3%.
Calithera Biosciences, Inc. Price and Consensus
Calithera Biosciences, Inc. Price and Consensus | Calithera Biosciences, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 13.1% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>